Recro Pharma (NASDAQ:REPH) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a note issued to investors on Monday.

Other research analysts have also issued reports about the company. Oppenheimer set a $18.00 target price on Recro Pharma and gave the stock a “buy” rating in a research report on Wednesday, September 5th. Roth Capital set a $9.00 target price on Recro Pharma and gave the stock a “buy” rating in a research report on Saturday, May 26th. BidaskClub raised Recro Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, May 24th. Janney Montgomery Scott cut their target price on Recro Pharma from $21.00 to $11.00 and set a “fair value” rating on the stock in a research report on Thursday, May 24th. Finally, Zacks Investment Research raised Recro Pharma from a “sell” rating to a “hold” rating in a research report on Thursday, May 31st. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $12.63.

Shares of REPH traded down $0.86 during trading hours on Monday, hitting $7.70. The stock had a trading volume of 167,900 shares, compared to its average volume of 270,197. The company has a current ratio of 1.59, a quick ratio of 1.42 and a debt-to-equity ratio of 2.22. The firm has a market capitalization of $172.37 million, a P/E ratio of -3.87 and a beta of -0.81. Recro Pharma has a 12-month low of $4.78 and a 12-month high of $13.05.

Recro Pharma (NASDAQ:REPH) last issued its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($1.34) by $0.72. The business had revenue of $21.74 million for the quarter, compared to analyst estimates of $16.81 million. Recro Pharma had a negative return on equity of 144.84% and a negative net margin of 75.19%. sell-side analysts predict that Recro Pharma will post -2.46 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its holdings in Recro Pharma by 211.8% in the 1st quarter. JPMorgan Chase & Co. now owns 98,751 shares of the specialty pharmaceutical company’s stock valued at $1,087,000 after purchasing an additional 67,078 shares in the last quarter. Cadence Capital Management LLC increased its holdings in Recro Pharma by 6.6% in the 2nd quarter. Cadence Capital Management LLC now owns 151,323 shares of the specialty pharmaceutical company’s stock valued at $760,000 after purchasing an additional 9,381 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Recro Pharma in the 1st quarter valued at $139,000. Sphera Funds Management LTD. acquired a new stake in Recro Pharma in the 1st quarter valued at $4,010,000. Finally, The Manufacturers Life Insurance Company increased its holdings in Recro Pharma by 6,480.5% in the 1st quarter. The Manufacturers Life Insurance Company now owns 235,712 shares of the specialty pharmaceutical company’s stock valued at $2,595,000 after purchasing an additional 232,130 shares in the last quarter. Hedge funds and other institutional investors own 55.86% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Read More: Stop Order Uses For Individual Investors

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.